This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yoshida S, Hayakawa K, Yamamoto A, Kuroda H, Imashuku S . The central nervous system complications of bone marrow transplantation in children. Eur Radiol 2008; 18: 2048–2059.
Barba P, Pinana JL, Valcarcel D, Querol L, Martino R, Sureda A et al. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1439–1446.
Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ . Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 300–308.
McKinney AM, Kieffer SA, Paylor RT, SantaCruz KS, Kendi A, Lucato L . Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 2009; 193: 192–206.
Lee MS, McKinney AM, Brace JR, Santacruz K . Clinical and imaging features of fludarabine neurotoxicity. J Neuroophthalmol 2010; 30: 37–41.
Ledet DS, Handgretinger R, Bertorini TE, Hale GA, Ribeiro RC, RB Khan . Leucoencephalopathy transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer. J Child Neurol 2008; 23: 1357–1362.
Chen X, Hale GA, Barfield R, Benaim E, Leung WH, Knowles J et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135: 524–532.
Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF . Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986; 70: 1225–1228.
Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW . Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 1986; 46: 5953–5958.
Warrell RP, Berman E . Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74–79.
Malspeis L, Grever MR, Staubus AE, Young D . Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17 (Suppl 8): 18–32.
Acknowledgements
This work was supported in part by a Center of Excellence Grant from the State of Tennessee, the Assisi Foundation of Memphis and the American Lebanese Syrian Associated Charities (ALSAC). This study was approved by the St Jude Institutional Review Board prior to data review.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
This study was presented in part at the American Society of Neuroradiology, New York, NY, USA, May 2012.
Rights and permissions
About this article
Cite this article
Helton, K., Patay, Z. & Triplett, B. Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation. Bone Marrow Transplant 48, 729–731 (2013). https://doi.org/10.1038/bmt.2012.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.196
This article is cited by
-
Fludarabine
Reactions Weekly (2013)